证券日报网1月7日讯 ，深赛格在接受调研者提问时表示，检验检测业务特性存在一定的区域性，公司 已形成一个总部、四个基地和十余个分支机构的总体布局，并将持续实现检验检测认证业务的优化布局 与拓展，提升市场竞争力和可持续发展能力。 （编辑 丛可心） ...

证券日报网讯 1月6日，道氏技术在互动平台回答投资者提问时表示，股价表现受多重因素影响。公司 将根据市场情况持续优化业务布局，脚踏实地把现有的业务做好，控制风险。同时，推进核心项目建 设，实现未来业务的创新引领和可持续发展，构建短、中、长期核心竞争力，保持公司健康、稳定、持 续向好发展，实现公司价值和股东利益最大化。目前，公司正在积极夯实固态电池材料工艺技术，有序 推进各材料板块的研发创新和市场推广工作，与下游客户的合作正在有序推进中。 （编辑 袁冠琳） ...

2025年12月29日，上海华谊集团股份有限公司以通讯表决方式召开第十一届董事会第十二次会议，应到 董事7人，实到7人，由董事长顾立立主持，部分高管列席。会议审议通过多项关键议案，涉及关联交 易、轮胎板块增资及薪酬改革等核心领域。 在业务发展层面，会议明确2026年预计日常关联交易总额310.48亿元，定价遵循市场或协议原则，该议 案尚需提交股东会审议。同时，审议通过双钱重庆公司3.5亿元增资进展议案，确认参股股东已同意双 钱集团单方非同比例增资，审计评估基准日调整为2025年11月30日，将强化对双钱重庆的控制与资金支 持，助力轮胎板块升级发展。 在公司治理方面，会议通过2025-2027年职业经理人薪酬改革、修订其他领导人员考核与薪酬方案等议 案，完成2024年度考核及2022-2024年任期激励结算，相关关联董事已回避表决。此次系列决议的落 地，将进一步优化公司业务布局与治理结构，为核心产业发展提供保障。 钱集团单方非同比例增资，审计评估基准日调整为2025年11月30日，将强化对双钱重庆的控制与资金支 持，助力轮胎板块升级发展。 在公司治理方面，会议通过2025-2027年职业经理人薪酬改革、修订其他 ...

Group 1 - The board of directors of China Software and Technology Service Co., Ltd. held its 27th meeting of the 8th session on December 8, 2025, via telecommunication voting [2][3][4] - The meeting was attended by all 7 directors, and the chairman, Chen Zhihua, presided over the meeting [3][4] Group 2 - The board approved a proposal to acquire 1% equity of the subsidiary Zhongruan Cloud Intelligence from the related party New Changcheng Technology Co., Ltd. for a price of 1.04411 million yuan [5] - Following the acquisition, Zhongruan Cloud Intelligence will be merged into the wholly-owned subsidiary Zhongruan Information Technology Innovation Co., Ltd., which will inherit all assets, liabilities, and rights of Zhongruan Cloud Intelligence [5][6] - As of June 30, 2025, Zhongruan Cloud Intelligence had total assets of 157.45 million yuan and net assets of 97.04 million yuan, with a revenue of 44.97 million yuan and a net profit of 1.57 million yuan for the first half of 2025 [6] - The transaction aims to optimize the company's business layout and asset structure, improve operational efficiency, and reduce management costs, aligning with the long-term interests of the company and its shareholders [6]

Group 1 - The company held its 14th meeting of the 9th Board of Directors on November 28, 2025, where the resolution to sell assets of its wholly-owned subsidiary was approved [1][2][3] - The assets being sold include the operational assets related to the municipal solid waste incineration power generation project in Mudanjiang, with a total transaction value of RMB 580 million [6][30] - The transaction does not require shareholder approval and is not classified as a related party transaction or a major asset restructuring [6][30] Group 2 - The buyer of the assets is the Mudanjiang Comprehensive Administrative Law Enforcement Bureau, a government agency with no existing related party relationships with the company [7][9][10] - The assets being sold include machinery, buildings, land use rights, inventory, and other operational assets, with a total book value of approximately RMB 580 million [11][12][14][30] - The sale is part of the company's strategy to optimize its business layout and resource allocation, aiming to enhance asset operation efficiency and overall profitability [30] Group 3 - The payment for the assets will be made in installments, with RMB 316 million due within five working days of the agreement's effectiveness, followed by additional payments by the end of December 2025 and January 2026 [20][21] - The company expects a reduction in net profit of approximately RMB 47 million for the fiscal year 2025 due to this transaction, although the impact on the company's ongoing operations is deemed minimal [30]

12月2日晚间，普莱柯（603566）生物工程股份有限公司(以下简称"普莱柯")公告称，公司拟认购中信 农业科技股份有限公司(以下简称"中信农业")持有的中普生物制药有限公司(以下简称"中普生物")4.04% 股权。 公告显示，中普生物由普莱柯、中牧实业股份有限公司(以下简称"中牧股份（600195）")和中信农业于 2018年6月共同出资成立，经营范围主要为口蹄疫疫苗业务；截至目前，普莱柯持股比例为46.97%，中 牧股份持股比例为48.99%，中信农业持股比例为4.04%。 中国商业经济学会副会长宋向清对《证券日报》记者表示，对普莱柯而言，拿下中普生物控制权可完善 其在畜牧疫病疫苗领域的布局，形成更完整的产品矩阵与业务协同。尤其是在畜牧业规模化发展的背景 下，口蹄疫作为畜禽重大疫病，其疫苗市场需求稳定，此次收购能为普莱柯锁定该领域的核心资产，符 合其长期发展规划。 公告显示，中普生物2024年以及今年上半年实现净利润分别亏损2620.74万元和1823.7万元。 对于上市公司收购亏损的参股公司股权现象，上海与梅管理咨询合伙企业合伙人沈萌接受《证券日报》 记者采访时表示，标的企业的经营表现无法满足财务投资者 ...

Core Viewpoint - Yuanli Co., Ltd. plans to acquire 100% equity of Tongsheng Co. through a combination of share issuance and cash payment, with a transaction price of 470.70 million yuan, aiming to enhance its business layout in the silicon dioxide sector and achieve synergistic effects [1] Group 1: Acquisition Details - The acquisition involves 11 counterparties, including Lu Yuanfang and Li Wei, among others [1] - The transaction price, excluding the amount for raising matching funds, is set at 47,070,000 yuan [1] Group 2: Company Profile - Tongsheng Co. is a high-tech enterprise specializing in the research, production, and sales of silicon dioxide, with significant industry recognition [1] - Its products are widely used in various downstream sectors, including rubber, lead-acid battery PE separators, toothpaste, feed additives, and coatings [1] Group 3: Strategic Implications - The completion of this restructuring will allow the company to optimize its business layout and enhance its ability for sustainable development in the main business [1] - The acquisition is expected to reduce recurring related-party transactions, avoid potential competition within the same industry, and improve the company's operational independence [1]

Core Viewpoint - Fujilai plans to deepen its existing business layout in the coming year, actively seizing market opportunities through product structure optimization, cost reduction, efficiency enhancement, and steady market expansion to achieve sustainable development and stable performance improvement [1] Group 1 - The company aims to optimize its product structure [1] - The company is focused on cost reduction and efficiency enhancement [1] - The company intends to steadily expand its market presence [1]

Core Viewpoint - The company is divesting its 80% stake in Jinhua Lianji Hospital for 1 yuan and transferring its debt of approximately 89.99 million yuan for 5.8 million yuan to optimize its healthcare service business and improve asset structure [1][2]. Group 1: Transaction Details - The company’s subsidiary, Junyao Medical, will transfer its 80% stake in Jinhua Lianji Hospital to Jinhua Lintian Biotechnology Co., Ltd. for 1 yuan [1]. - The debt owed to Junyao Medical by Jinhua Lianji, amounting to approximately 89.99 million yuan, will be transferred for 580,000 yuan [1]. - Since its acquisition in March 2022, Jinhua Lianji Hospital has incurred cumulative losses of 79.15 million yuan [1]. Group 2: Financial Impact - The transaction is expected to reduce the company's consolidated net profit attributable to shareholders by 34.25 million yuan in 2025 [2]. - The company reported a total revenue of 2.645 billion yuan for the first three quarters of 2025, a year-on-year decrease of 4.23% [2]. - The net profit attributable to shareholders for the same period was 55.66 million yuan, down 33.12% year-on-year [2]. Group 3: Company Background - The company, founded in 1988, is a leading commercial retail service enterprise in Wuxi and became the first commercial retail company listed in Jiangsu Province in 2002 [2]. - It is a member of the Junyao Group and serves as the main entity for the modern consumption sector of the group [2]. - After the divestment of Jinhua Lianji, the company still holds assets in the healthcare sector, including Junyao Pediatrics and Yaan Health, but is currently focusing on cost reduction and strategic restructuring [2].

Core Viewpoint - The company, Da Dongfang, announced the transfer of 80% equity and debt claims of Jinhua Lianji Hospital to Jinhua Lin Tian Biotechnology Co., aiming to optimize its healthcare service business structure due to ongoing losses since acquisition [1] Group 1: Transaction Details - Shanghai Junyao Medical Health Technology Co., a subsidiary of Da Dongfang, plans to transfer 80% of its equity in Jinhua Lianji Hospital for 1 yuan [1] - The debt claims held by Junyao Medical against Jinhua Lianji amount to approximately 89.991 million yuan, which will be transferred for 5.8 million yuan [1] Group 2: Financial Performance - Since the acquisition in March 2022, Jinhua Lianji Hospital has incurred cumulative losses of 79.15 million yuan up to September 2025 [1] - The hospital has not reached a break-even point due to changes in the market environment and healthcare policies since 2022 [1] Group 3: Strategic Intent - The company aims to enhance service scale and operational efficiency through a professional management team and market-oriented operations [1] - The transfer of equity and debt is part of a strategy to optimize the asset structure and improve the quality and efficiency of the healthcare business segment [1]